Immunology

FDA accepts Intercept’s resubmitted NDA for obeticholic acid

Nonalcoholic steatohepatitis (NASH) is described as a subgroup of nonalcoholic fatty liver disease (NAFLD), where excessive fat buildup is accompanied…

Study finds higher suicide rate among patients with severe health conditions

As the stigma surrounding mental health continues to diminish, health professionals have begun to shed light on the risk of…

Hutchmed completes subject enrolment in ITP therapy trial

Hutchmed has completed participant enrolment in a Phase III ESLIM-01 clinical trial of sovleplenib for primary immune thrombocytopenia (ITP), in…

Petition to update US alcohol warning label could prevent many cancer cases

In October 2020, eight public health advocacy groups filed a petition urging the US Treasury Department’s Alcohol and Tobacco Tax…

Systemic lupus erythematosus: major drug trials to watch in 2022 and 2023

Systemic lupus erythematosus (SLE), the most common type of lupus, is an autoimmune disease that causes the body to attack…

Pipeline agents to improve the management of pruritus in atopic dermatitis

Anti-itch agents are becoming more prominent in the atopic dermatitis (AD) therapeutic space with multiple new product candidates in the…

Kezar to commence Phase IIa autoimmune hepatitis therapy trial

Kezar Life Sciences has announced plans to commence the Phase IIa PORTOLA clinical trial (KZR-616-208) of zetomipzomib to treat autoimmune…

EADV 2022: Dupixent shows sustained efficacy across anatomical regions in children

Sanofi and Regeneron presented analyses from the LIBERTY AD PRESCHOOL (NCT03346434) study of interleukin (IL)-4/13 inhibitor, Dupixent (dupilumab), at the…

Pipeline Moves: Novartis completes Phase II Sjögren’s syndrome trial, advancement prospects jump

This week on Pipeline Moves, we look into the Novartis completion of a Phase II trial in Sjögren's syndrome. We…

Pipeline Moves: Nektar terminates Phase I/II cancer trial, further study shot in seven indications drop

In this week’s edition of Pipeline Moves, the Clinical Trials Arena team studies Nektar Therapeutics’s termination of a Phase I/II…